Catherine M. Klema's most recent trade in OptimizeRx Corp was a trade of 9,868 Common Stock done . Disclosure was reported to the exchange on June 11, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| OptimizeRx Corp | Catherine M. Klema | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 9,868 | 21,620 (0%) | 0% | 0 | Common Stock | |
| OptimizeRx Corp | Catherine M. Klema | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2025 | 5,109 | 11,752 (0%) | 0% | 0 | Common Stock | |
| OptimizeRx Corp | Catherine M. Klema | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2025 | 5,109 | 0 | - | - | Restricted Stock Units | |
| OptimizeRx Corp | Catherine M. Klema | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 6,643 | 6,643 (0%) | 0% | 0 | Common Stock | |
| OptimizeRx Corp | Catherine M. Klema | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2024 | 5,109 | 5,109 | - | - | Restricted Stock Units |